Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

BACKGROUND: Despite having milder symptoms than adults, children are still susceptible to and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to curtail the pandemic. Among the available COVID-19 vaccine platforms, an inactivated vaccine platform has the advantage o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadrevu, Krishna Mohan, Reddy, Siddharth, Jogdand, Harsh, Ganneru, Brunda, Mirza, Nizam, Tripathy, Virendra Nath, Singh, Chandramani, Khalatkar, Vasant, Prasanth, Siddaiah, Rai, Sanjay, Ella, Raches, Blackwelder, William, Prasad, Sai, Ella, Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212880/
https://www.ncbi.nlm.nih.gov/pubmed/35717995
http://dx.doi.org/10.1016/S1473-3099(22)00307-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212880/
https://www.ncbi.nlm.nih.gov/pubmed/35717995
http://dx.doi.org/10.1016/S1473-3099(22)00307-3

Ejemplares similares